Developmental Therapeutics

发育治疗学

• 批准号: 10626501
• 负责人: Dustin A Deming
• 金额: $ 14.08万
• 依托单位: UNIVERSITY OF WISCONSIN-MADISON
• 依托单位国家: 美国
• 财政年份: 1997
• 资助国家: 美国
• 起止时间: 1997-04-25 至 2028-03-31
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10626501
• 关键词: Address; Adult; Advanced Malignant Neoplasm; Antibodies; Antibody-drug conjugates; Applied Research; Award; Basic Science; Biological Markers; Cancer Center; Cancer Patient; Catchment Area; Cell Therapy; Child; Chromosomal Instability; Clinical; Clinical Research; Clinical Trials; Collaborations; Combination immunotherapy; Communities; Comprehensive Cancer Center; Consultations; Dedications; Dendritic Cell Vaccine; Destinations; Development; Developmental Therapeutics Program; Direct Costs; Disease; Flow Cytometry; Fostering; Funding; Goals; Grant; Head and Neck Cancer; Hematologic Neoplasms; Image; Immune; Immune checkpoint inhibitor; Immunotherapeutic agent; Immunotherapy; Instruction; Journals; Leadership; Lymphoma; Macrophage; Malignant Neoplasms; Mentorship; Mesenchymal Stem Cells; Mission; Molecular Target; Multiple Myeloma; Natural Immunity; Natural Killer Cells; Patient-Focused Outcomes; Patients; Peer Review; Pharmaceutical Preparations; Phase; Phase II/III Trial; Prostate; Publications; Regulation; Research; Research Personnel; Resistance; Schools; Science; Solid Neoplasm; Source; Strategic Planning; TP53 gene; Therapeutic; Therapeutic Agents; Therapy Clinical Trials; Training Programs; Translating; Translational Research; Translations; United States National Institutes of Health; Validation; Work; adaptive immunity; bench to bedside; biomarker development; biomarker driven; biomarker validation; candidate identification; chimeric antigen receptor T cells; clinical translation; college; drug development; drug discovery; early phase clinical trial; effective therapy; immune-related adverse events; improved; inter-institutional; lead candidate; malignant breast neoplasm; meetings; member; molecular drug target; monocyte; novel; novel therapeutics; patient oriented; pre-clinical; pre-clinical research; precision medicine; programs; response; success; targeted cancer therapy; targeted treatment; taxane; therapeutic development; treatment strategy; tumor

UWCCC DEVELOPMENTAL THERAPEUTICS (DT) PROGRAM Co-leaders: Christian Capitini, Beth Weaver, and Dustin Deming PROJECT SUMMARY/ABSTRACT The discovery, development, and translation of new biomarkers and therapeutics are critical to improve the clinical outcomes for patients with cancer in our catchment area and beyond. The mission of the UW Carbone Cancer Center (UWCCC) Developmental Therapeutics (DT) Program is to improve cancer patient outcomes by discovering new targets, developing new therapies and biomarkers, and translating preclinical research into phase I-III clinical trials. The DT Program provides translational direction not only for DT members, but also for the basic science programs within the UWCCC, including GEM, VR, and TM. Our community influenced bench- to-bedside and bedside-to-bench research enables a greater understanding of mechanisms of response and resistance which enable the discovery and development of new drugs, biomarkers, and therapeutic strategies. The DT Program has 56 core members, representing 20 departments and 5 different schools/colleges. Research impacts of DT members are evidenced by research awards totaling $20.8M in annual direct cost of peer-reviewed and non-peer reviewed funding (including $5.41M NCI, $5.06M cancer-related other NIH agencies, $3.25M peer- reviewed non-NIH sources, $7.05M non-peer reviewed funding) and a significant number of publications (1,011 publications, 12% of which result from intra-programmatic collaboration, 31% from inter-programmatic work and 55% from inter-institutional work). Of note, 29% were publications in high impact journals (impact factor > 10). The thematic aims of the DT program are to: 1) discover and develop combination immunotherapy approaches that bridge innate and adaptive immunity for treatment of advanced cancers; 2) discover and develop new drug molecular targets, precision medicine therapies, and biomarkers; and 3) translate new immunotherapeutic approaches and precision medicine therapies to clinical trials, including phase I-III studies. To address these aims, members of the DT Program come from basic science, applied science, and clinical departments. This program has expertise in therapeutic discovery and development across immunotherapy/cell therapy and precision medicine therapies. Additionally, translational and clinical research DT program members apply intra- and inter-programmatic research discoveries in clinical trials. DT members are performing the majority of investigator-initiated early phase studies and advance UWCCC science into phase II and III clinical trials with an emphasis on diseases that are high priority for our catchment area, including breast cancer, lymphoma/myeloma, prostate, and head and neck cancers. Finally, the DT program is dedicated to the mentorship of junior investigators as part of formalized training programs, and also through DT-led meetings, pilot grants, and mentorship from the DT leadership.

UWCCC 发育治疗 (DT) 计划 联合领导者：克里斯蒂安·卡皮蒂尼 (Christian Capitini)、贝丝·韦弗 (Beth Weaver) 和达斯汀·戴明 (Dustin Deming) 项目概要/摘要 新生物标志物和疗法的发现、开发和转化对于改善 我们学区及其他地区癌症患者的临床结果。威斯康星大学卡本分校的使命 癌症中心 (UWCCC) 发育治疗 (DT) 计划旨在改善癌症患者的治疗结果 通过发现新靶标、开发新疗法和生物标志物以及将临床前研究转化为 I-III期临床试验。 DT 计划不仅为 DT 成员提供翻译指导，还为 UWCCC 内的基础科学项目，包括 GEM、VR 和 TM。我们的社区影响了板凳- 床边和床边到工作台的研究可以更好地理解反应机制和 耐药性使得新药、生物标志物和治疗策略的发现和开发成为可能。 DT计划有56名核心成员，代表20个院系和5个不同的学校/学院。研究 DT 成员的影响通过同行评审的年度直接成本总计 2080 万美元的研究奖励得到证明 和非同行评审资金（包括 541 万美元 NCI、506 万美元癌症相关其他 NIH 机构、325 万美元同行评审资金） 审查的非 NIH 来源、705 万美元的非同行审查资金）和大量出版物（1,011 出版物，其中 12% 来自计划内合作，31% 来自计划间工作和 55% 来自机构间工作）。值得注意的是，29% 是在高影响力期刊（影响因子 > 10）上发表的论文。 DT 计划的主题目标是：1）发现和开发联合免疫治疗方法 连接先天免疫和适应性免疫以治疗晚期癌症； 2）发现和开发新药 分子靶标、精准医学疗法和生物标志物； 3）转化新的免疫疗法 临床试验的方法和精准医学疗法，包括 I-III 期研究。为了解决这些 目标，DT计划成员来自基础科学、应用科学和临床科室。这 该计划拥有免疫疗法/细胞疗法的治疗发现和开发方面的专业知识， 精准医学疗法。此外，转化和临床研究 DT 计划成员应用内部 以及临床试验中的跨项目研究发现。 DT 成员执行大部分 研究者发起的早期研究，并将 UWCCC 科学推进到 II 期和 III 期临床试验 强调我们学区高度重视的疾病，包括乳腺癌、淋巴瘤/骨髓瘤、 前列腺癌、头颈癌。最后，DT 计划致力于对初级学生的指导 作为正式培训计划的一部分，以及通过 DT 主导的会议、试点资助和 来自 DT 领导层的指导。